Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig in Advanced/Metastatic Solid Tumors
NCT06535607Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2 trial of volrustomig in solid tumor, Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC) and 2 more (8 arms), sponsored by AstraZeneca. Primary endpoints: Objective Response Rate at 4 years and Adverse Events and Serious Adverse Events at 4 years. Started Aug 2024; status: recruiting.
02
Drugs
volrustomig
03
Conditions
solid tumorCervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)pleural mesothelioma
Beyond the preview
Go deeper on NCT06535607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535607.